
Capital for medical devices didn't dry up. It got choosy.
Medtech venture in 2026 is disciplined. In digital health where the numbers are clearest, global funding reached $28.8B in 2025 up 9%, Europe grew faster than any other region at 15%, and AI-enabled companies absorbed 54% of US digital-health dollars. The money also concentrated into fewer, larger rounds. Traditional devices, diagnostics and hardware raise on their own patterns, so read these figures as the digital-health signal rather than a single medtech number.
What investors underwrite now depends on stage and category, but the through-line is evidence. Credible technical and clinical proof, early commercial validation, and a clear regulatory and revenue/reimbursement plan where reimbursement applies. Investors also treat a shaky device classification, over-simplified evidence requirements and unknown EU CE-pathway questions as diligence risk, and an unclear pathway adds cost and delays development. They want you to be clear on these so their bet doesn’t get stuck in the valley of death.
This is a curated directory, not a ranking by deal count. We picked firms on healthcare investment activity, current deployable funds, a stated medtech or digital-health mandate, and relevance to founders as of August 2026. Several firms below also invest across therapeutics and biotech, so check each mandate against your own category before you reach out. Primary focus, stage and geography are noted for each.
European investor doors worth knocking on
- Sofinnova Partners. Paris, London and Milan. Healthcare specialist whose platform includes the MD Start medical-device accelerator and Capital XI, a €650M ($750M) early-stage healthcare fund that closed in November 2025, investing across biotech and medtech. Focusing on devices, biotech and digital health. Early stage.
- Gilde Healthcare. Utrecht, Frankfurt, and Boston. Healthcare specialist across venture, growth and private equity in digital health, medtech and therapeutics. The latest venture and growth fund is Venture & Growth VI, €740M, closed November 2023, writing €10-70M per company. Focusing on digital health, devices and therapeutics. Venture to growth stage. European and US geographical focus.
- HealthCap. Stockholm and Lausanne. Healthcare and life-sciences specialist with a strong Nordic device and medtech track record. Focusing on devices and biotech. Early to growth stage.
- Wellington Partners. Munich. Long-standing early-stage life-sciences investor across medical devices and biotech, life-sciences-weighted. Focusing on devices and biotech. Early stage.
- Heal Capital. Berlin. Healthcare specialist backed by German private health insurers, €200M+ AUM, investing in digital health, care delivery tools, health-system infrastructure, and AI while explicitly not drugs or therapeutics. Leading or co-leading with €1-5M investment. Pre-seed to Series A stage.
- MTIP. Basel. Healthcare-technology growth investor focused on AI-enabled and software-driven B2B businesses. Growth stage with up to €30M investment per ticket.
- Andera Partners. Paris and Munich. Multiple funds, with a dedicated LIfe Sciences fund for therapeutics and medical innovations (medtech) with €15M to €60M invested per ticket on average. Early stage through growth stage.
- Kurma Partners. Paris. Multiple funds with focus on biotechnology therapeutics but a dedicated fund for seed stage diagnostic companies and growth stage medtech / healthtech growth companies. Seed to venture stage.
- Nina Capital. Barcelona and Palo Alto. Healthtech-only specialist founded in 2019. Fund III first-closed at €50M in February 2025, writing €250k-1.5M cheques. Focusing on early stage healthtech. Pre-seed to Series A stage. European and US geographical focus.
- Panakès Partners. Milan. Italian life-sciences specialist investing across Biotech and medtech. The Purple fund reached a €175M final close in February 2023 and backs companies at all stages across Europe, the UK, Switzerland, Israel and the US. Focusing on medtech and Biotech. Early to growth stage.
- Heran Partners. Brussels. Healthtech and medtech specialist backing tools that add efficiency, data and scale across healthcare and life-sciences R&D. Healthtech Fund II closed at €90M in February 2026. Seed to Series A/B stage.
- Capricorn Partners. Leuven. Multiple funds with some dedicated to digital health and medtech covering both traditional devices and health-software platforms. Healthtech Fund II first-closed at €51M in January 2025 with a boost in November, writing €1-5M into 10-15 companies. Late seed to Series B stage.
- EQT. Global offices (25+). A multi-fund firm targeting life sciences, drug discovery, dimensions, health economics, and medical innovation. Some funds writing checks for roughly €10-60M while others are late growth stages and higher. Growth to commercial stage. European geographical focus with global reach.
- Ship2B Ventures. Barcelona. Impact investor with multiple funds targeting child health, aging and climate with check sizes ranging from €100K to €4M. Pre-seed to Series A.
Featured Fund: Heal Capital
Berlin-based Heal Capital is unusual in that it is backed by more than 25 private health insurers alongside the European Investment Fund. That insurer base gives founders unusually direct access to private-payer thinking, reimbursement and market-access expertise in Germany. It is an important private-payer network, not the whole of Germany's or Europe's payer system, which varies country by country. Heal says its insurer and partner network helps portfolio companies with customer access, reimbursement and market access. Its portfolio runs to more than 30 companies, with exits including Siilo (acquired by Doctolib in 2023) and FORMEL Skin, and portfolio names such as Gleamer, the radiology-AI firm whose Series B it co-led in 2023. Full disclosure, Heal Capital is an investor in Dovetail Regulatory, so we're biased, though the insurer network genuinely is rare.
The one gap that decides the round
The bar that keeps coming up in 2026 investor conversations is the one many teams leave late. Regulatory strategy and a reimbursement path where reimbursement applies. That is the gap Dovetail is built to close, an embedded expert regulatory team working through a purpose-built, validated compliance platform, so teams get to market faster without hiring in-house.
Better served warm
Building a medical device can be hard, but fundraising doesn't have to be. At Dovetail, we've spent years building close relationships with investors, accelerators, and founders, and we’re here to put them to work for medtech teams. With our investor matchmaking and regulatory readiness program, we match you with the right investor for your device, and we get your regulatory strategy vetted by our experts so it stands up to scrutiny. By the time we make a warm intro, our investors already understand how you've de-risked your path to market and why you're ready to be the next big thing.
If you're a medtech team looking to raise, you can apply to be a part of the program at no charge to you. If you're an investor looking for your next portfolio company get it touch.


